<SEC-DOCUMENT>0001193125-25-256667.txt : 20251029
<SEC-HEADER>0001193125-25-256667.hdr.sgml : 20251029
<ACCEPTANCE-DATETIME>20251029171614
ACCESSION NUMBER:		0001193125-25-256667
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20251029
DATE AS OF CHANGE:		20251029

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Virax Biolabs Group Ltd
		CENTRAL INDEX KEY:			0001885827
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-94426
		FILM NUMBER:		251430979

	BUSINESS ADDRESS:	
		STREET 1:		BIOCITY GLASGOW
		STREET 2:		BO'NESS ROAD, NEWHOUSE
		CITY:			LANARKSHIRE
		STATE:			X0
		ZIP:			ML1 5UH
		BUSINESS PHONE:		44 020 7788 7414

	MAIL ADDRESS:	
		STREET 1:		BIOCITY GLASGOW
		STREET 2:		BO'NESS ROAD, NEWHOUSE
		CITY:			LANARKSHIRE
		STATE:			X0
		ZIP:			ML1 5UH

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Virax Biolabs (Cayman) Ltd
		DATE OF NAME CHANGE:	20210930

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Foster James Alexander Cunliffe
		CENTRAL INDEX KEY:			0001988784
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	MAIL ADDRESS:	
		STREET 1:		20 NORTH AUDLEY STREET
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 6LX
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001988784</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>3</amendmentNo>
      <securitiesClassTitle>Ordinary Shares</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>03/31/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001885827</issuerCik>
        <issuerName>Virax Biolabs Group Limited</issuerName>
        <issuerCusip>G9495L125</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <street1 xmlns="http://www.sec.gov/edgar/common">BioCity Glasgow, Bo'Ness Road Newhouse</street1>
          <city xmlns="http://www.sec.gov/edgar/common">Lanarkshire</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">X0</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">ML1 5UH</zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(d)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>James Foster</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>X0</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>368570</soleVotingPower>
        <sharedVotingPower>0</sharedVotingPower>
        <soleDispositivePower>368570</soleDispositivePower>
        <sharedDispositivePower>0</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>368570</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>8.3</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>(1) Includes options to purchase (a) 63,916 ordinary shares which vested on April 18,2024, and (b) 16,667 ordinary shares which vested on April 18,2025. Adjusted retroactively for 1-for-10 reverse stock split which became effective on December 18, 2023.

(2) Percentage based on 4,341,956 ordinary shares outstanding on March 31, 2025, adjusted retroactively for 1-for-10 reverse stock split which became effective on December 18, 2023.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Virax Biolabs Group Limited</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>BioCity Glasgow Bo'Ness Road Newhouse, Lanarkshire, United Kingdom, ML 1 SUH</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>James Foster</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>BioCity Glasgow Bo'Ness Road Newhouse, Lanarkshire, United Kingdom, ML 1 SUH</principalBusinessOfficeOrResidenceAddress>
        <citizenship>United Kingdom</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>368,570</amountBeneficiallyOwned>
        <classPercent>8.3</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>368,570</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>368,570</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>Y</notApplicableFlag>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>James Foster</reportingPersonName>
      <signatureDetails>
        <signature>James Foster</signature>
        <title>Chief Executive Officer</title>
        <date>10/28/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
